FI116904B - Procedure for changing the composition of the milk and the use of the milk - Google Patents
Procedure for changing the composition of the milk and the use of the milk Download PDFInfo
- Publication number
- FI116904B FI116904B FI20031538A FI20031538A FI116904B FI 116904 B FI116904 B FI 116904B FI 20031538 A FI20031538 A FI 20031538A FI 20031538 A FI20031538 A FI 20031538A FI 116904 B FI116904 B FI 116904B
- Authority
- FI
- Finland
- Prior art keywords
- milk
- ruminant
- raw material
- yeast
- immune
- Prior art date
Links
- 235000013336 milk Nutrition 0.000 title claims description 50
- 239000008267 milk Substances 0.000 title claims description 50
- 210000004080 milk Anatomy 0.000 title claims description 50
- 238000000034 method Methods 0.000 title claims description 29
- 239000000203 mixture Substances 0.000 title description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 26
- 229940099472 immunoglobulin a Drugs 0.000 claims description 22
- 244000309466 calf Species 0.000 claims description 19
- 241000282849 Ruminantia Species 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 14
- 210000003022 colostrum Anatomy 0.000 claims description 12
- 235000021277 colostrum Nutrition 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229940088592 immunologic factor Drugs 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 claims 1
- 102000004407 Lactalbumin Human genes 0.000 claims 1
- 108090000942 Lactalbumin Proteins 0.000 claims 1
- 101710136733 Proline-rich protein Proteins 0.000 claims 1
- -1 cytoclysozyme Proteins 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000005965 immune activity Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 7
- 230000008774 maternal effect Effects 0.000 description 6
- 239000000367 immunologic factor Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000271532 Crotalus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000022676 rumination Effects 0.000 description 1
- 208000015212 rumination disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/153—Nucleic acids; Hydrolysis products or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
Description
MENETELMÄ MAIDON KOOSTUMUKSEN MUUTTAMISEKSI JA KÄYTTÖMETHOD FOR MODIFICATION AND USE OF MILK COMPOSITION
Keksinnön kohteena on patenttivaatimu johdanto-osassa määritelty menetelmä maidon kooi 5 sen muuttamiseksi, patenttivaatimuksen 2 jo] osassa määritelty menetelmä maidontuotannon m seksi, patenttivaatimuksen 3 johdanto-osassa mäi ty menetelmä immuniteetin nostamiseksi sekä pai vaatimuksen 12 johdanto-osassa määritelty maidoi 10 to kasvun edistämiseksi.The invention relates to a method for changing milk size as defined in the preamble of claim 1, a method for increasing milk production as defined in claim 2, a method for increasing immunity as defined in the preamble of claim 3, and promoting milk growth as defined in the preamble of claim 12.
Hakemuksessa maidolla tarkoitetaan te: toa ja maitoa yleisesti.In the application, milk refers to you and milk in general.
Useissa eläinlajeissa vasta-aineita i emältä poikaselle istukan kautta tiineysaikana.In many animal species, antibodies from mother to baby through the placenta during gestation.
15 tijoiden kohdalla emän vasta-aineita ei siirry : läpi, jolloin vasikan vastustuskyky on syntymäin huono. Vasikan passiivisen immuniteetin muodosi onkin täysin emältä saadun maidon ja erityisest nimaidon laadun varassa.Females do not pass through the maternal antibodies: the calf's resistance to birth is poor. Therefore, your form of passive immunity in a calf is entirely dependent on the quality of the milk obtained from the mother and, in particular, of the milk.
20 Ternimaidolla tarkoitetaan maitoa, jot daan emältä heti poikimisen jälkeen ja korkeint tuntia poikimisen jälkeen. Vastasyntyneelle vai välttämättömän maidon laadulla tarkoitetaan sen « « :,V tämiä vitamiini- ja valkuaispitoisuuksia seki • 25 ruumiissa kehittyneitä vasta-ainepitoisuuksia, : suojaavat vasikkaa tautitartunnoilta. Märeht:20 Colostrum is milk that is delivered from the mother immediately after calving and up to an hour after calving. Newborn or essential milk quality refers to its ««:, Vitamin and Protein levels, and • Antibody • developed in the body: protects the calf against infections. chewing:
·...· maidon vasta-aineista on immunoglobuliini G· ... · milk antibodies are immunoglobulin G
yleisin ja sen vaikutusta emän ja poikasen suoj; sa patogeenisten organismien aiheuttamia taut< t f 30 infektioita vastaan on tutkittu laajasti. Immune liini G:n lisäksi märehtijöiden maito käsittää • · · 4 2 immunisoimalla märehtijä antigeenillä, joka ai. vasta-aineen tuoton märehtijässä.most common and its effect on the protection of the mother and the chick; Disease infections caused by pathogenic organisms have been extensively studied. In addition to Immune lineage G, ruminant milk comprises • · · 4 2 by immunizing ruminants with the antigen of a. antibody production in the ruminant.
US-patenttihakemuksessa 2003/0074676 esitetty menetelmä märehtijän ja sen maidon IgA 5 suuden nostamiseksi immunisoimalla märehtijä ha! antigeenillä. Menetelmässä tiineelle märehtijäi netaan antigeeniä vähintään kahden eri reitin, utareensisäisen, suonensisäisen ja vatsaontelo] sen reitin, kautta immuniteettivaikutuksen aik< 10 miseksi. Tämän jälkeen märehtijälle annetaan geeniä kolmannen reitin kautta, joka on valittu luetelluista kolmesta reitistä ja on eri kuin aikaisemmin käytettyä reittiä. Saatua IgA-p: maitoa käytetään valmistettaessa farmaseuttisia 15 meettisia ja/tai eläinlääkintäkoostumuksia sekä tuotteita ja/tai ravinnon lisäaineita.U.S. Patent Application 2003/0074676 discloses a method for raising the ruminant and its milk IgA 5 by immunizing a ruminant ha! with an antigen. In the method, a pregnant ruminant is provided with antigen via at least two different routes, the udder, the intravenous route, and the intraperitoneal route, to elicit an immune effect. The ruminant is then given a gene via a third pathway selected from the three pathways listed and different from the route previously used. The resulting IgA-β: milk is used in the preparation of pharmaceutical and / or veterinary compositions as well as products and / or nutritional additives.
Ongelmana tunnetussa immunointimem käytössä on menetelmän vaatimat monimutkaiset ! nänomaiset toimenpiteet, joita kasvattaja ei it£ 20 ty suorittamaan, menetelmän vaatima työ ja kest saksi immunisaation tehostamiseksi suositellaan rokotuksia.The problem with known immunization is the complexity required by the method! these procedures, which the breeder does not do £ 20, the amount of work required and the duration of the procedure Vaccinations are recommended to boost the immunization.
Keksinnön tarkoituksena on tuoda esii :V: ja yksinkertaisempi menetelmä märehtijän maidi :’·*· 25 muuni teki joiden pitoisuuden nostamiseksi antama! * ψ : rehtijälle hydrolyyttisesti käsiteltyä hiive ** * · ainetta. Lisäksi keksinnön tarkoituksena on * * esiin menetelmä märehtijän poikimisen jälkeise i ♦ dontuot annon nostamiseksi sekä menetelmä märe • * *···*' 30 poikimisen jälkeisen alentuneen immuniteetin ne seksi antamalla märehtijälle hydrolyyttisesti k£ • « « M ,11 , 3The object of the invention is to provide a pre: V: and a simpler method of ruminant milk: '· * · 25 others made with increasing concentration given by! * ψ: hydrolytically treated yeast ** * · substance. It is a further object of the invention to * * provide a method for increasing the delivery of post-partum ruminants and a method for providing reduced immunity post-parturition by hydrolytically administering to the ruminant.
Keksinnölle tunnusomaisten seikkojen viitataan patenttivaatimuksiin.Aspects of the invention are referred to in the claims.
Keksintö perustuu suoritettuun tutki hön, jonka yhteydessä yllättäen havaittiin, 5 maidon immuunitekijoiden pitoisuus korreloi erityisesti vasikoiden kasvun, kanssa ja et muunitekijoiden pitoisuutta maidossa pystyttiin maan antamalla märehtijälle ruokinnan yhteydessä merkiksi rehussa, hydrolyyttisesti käsiteltyä 10 raaka-ainetta. Samassa yhteydessä havaittiin hydrolyy11 inen hi ivaraaka-aine nopeut ti immuni vasteen palautumista poikimisen jälkeen ja ] maidontuotantoa.The invention is based on a study which surprisingly found that the concentration of immune factors in milk was particularly correlated with the growth of calves, and that the concentration of non-milk factors in the milk was achieved by giving the ruminant feed 10 hydrolytically treated feed materials. At the same time, the hydrolytic high-grade raw material accelerated the recovery of the immune response after calving and milk production.
Keksinnön mukaisissa menetelmissä märe] 15 le annetaan maidon immuunitekijoiden pitoisuutt tava määrä hydrolyyttisesti käsiteltyä hiivi ainetta.In the methods of the invention, the lubricant is administered in a concentration of hydrolytically treated yeast of milk immune factors.
Maidon immuunitekijöitä ovat immunogl< nit (IgA, IgD, IgE, IgG ja IgM), proliini-rikka* 20 teiinit (PRP), laktoferriini, glykoproteiinit, i bumiinit, sytokiinit, lysotsyymit, entsyymit, kosyytit, nukleotidit ja/tai muut vastaavat ma: muunitekijät.Immune factors in milk include immunoglobulins (IgA, IgD, IgE, IgG, and IgM), proline-rich * 20 teins (PRP), lactoferrin, glycoproteins, insulin, cytokines, lysozymes, enzymes, cytosides, nucleotides and / or : other factors.
• * V,· Eräissä edullisissa sovellutuksi ssc 2 5 muunitekijänä on immunoglobuliini A (IgA) .• * V, · In some preferred applications, the ssc 2 5 modifier is immunoglobulin A (IgA).
• Hiivaraaka-aine voi olla mitä tahans nettua hiivaa kuten panimo-, leivin- ja/tai muut taavaa ravinnoksi soveltuvaa hiivaa ja edullises e * nimohiivaa.• The yeast raw material may be any yeast, such as brewing, baking and / or other edible yeast and preferred yeasts.
» « *·** 3 0 Hydrolyyttisesti käsitellyllä hiiv< aineella tarkoitetaan hiivaraaka-ainetta, jota » * 9 τ ( 4 pneumaattinen voima. Käsittelyllä lisätään ja/tai polysakkaridien, betaglukaanin ja/tai p: nien efektiivistä konsentraatiota liukenemattom: lurakenteiden pinnalla ja/tai vapautetaan mai] 5 komponentteja.»« * · ** 3 0 Hydrolytically treated yeast is a yeast raw material which »* 9 τ (4 pneumatic force. The treatment increases and / or the effective concentration of polysaccharides, betaglucan and / or p insoluble on the surface of the yeast structures and / or releasing the maize components.
Hiivaraaka-aine voidaan haluttaessa su< ennen hydrolyyttistä käsittelyä.If desired, the yeast feedstock may be pre-hydrolytic treated.
Hydrolyyttisesti käsiteltyä hiiv; ainetta voidaan antaa märehtijälle ravinnon yhl 10 sä. Se voidaan antaa yhdessä rehun kuten karkea ki- ja/tai juomarehun kanssa tai rehuun sekoitetHydrolytically treated yeast; the substance may be administered to a ruminant in more than 10 diets. It may be administered with a feed such as coarse feed and / or feed or mixed with feed
Mainittua hiivaraaka-ainetta voidaan märehtijälle ennen poikimista, esimerkiksi 1 - < koa, edullisesti noin 2 viikkoa ennen poikimist 15 nen poikimista mainittua hiivaraaka-ainetta τ antaa määränä 0,1 - 0,3 %, edullisesti 0,14 - ja edullisemmin 0,2 % päivittäisestä ruoka-anne kuiva-aineena laskettuna.Said yeast raw material may be administered to the ruminant prior to calving, for example 1 to <2 weeks, preferably about 2 weeks prior to calving, in an amount of 0.1 to 0.3%, preferably 0.14 to 0, and more preferably 0.2 % of your daily food intake expressed as dry matter.
Mainittua hiivaraaka-ainetta voidaan 20 märehtijälle myös poikimisen jälkeen, esimerkik 12 viikkoa, edullisesti 5-10 viikkoa poikimise keen. Vastaavalla tavalla voidaan märehtijälle misen jälkeen antaa mainittua hiivaraaka-c :V: määränä 0,01 - 0,1 %, edullisesti 0,03 - 0,01 • · ·*·*; 25 edullisemmin 0,04 - 0,06 % päivittäisestä ·· « : .*♦ annoksesta kuiva-aineena laskettuna.Said yeast raw material can also be given to 20 ruminants after calving, for example 12 weeks, preferably 5 to 10 weeks before calving. Similarly, after rumination, said yeast raw c: V may be administered in an amount of 0.01 to 0.1%, preferably 0.03 to 0.01 • · · * · *; 25 more preferably 0.04-0.06% of the daily dose of ···: * ♦ calculated on a dry basis.
• # · ··* ♦• # · ·· * ♦
Esillä olevan keksinnön mukaisesti vain • * tua maitoa voidaan käyttää kasvun, erityisesti ♦ · koiden kasvun, edistämiseksi.According to the present invention, only • * milk can be used to promote growth, especially ♦ · growth of dogs.
• · *···*. 3 0 Keksinnön mukaisesti valmistettua tez toa, jonka immuunitekijoiden pitoisuutta on ne • » · „ . . .• · * ··· *. 3 0 Teas produced according to the invention having a concentration of immune factors. . .
• « I__i M .i. A^ . I. M «. ^ 1 Ί . _ t J _ .. _ _ 7___ _ _ ^ ^ 5 tamista voidaan jatkaa myös aina 4-5 viikor asti. Ternimaidon/maidon lisäksi vasikoita ^ ruokkia millä tahansa tavanomaisella juoma-, vs karkearehulla.• «I__i M .i. A ^. I. M «. ^ 1 Ί. _ t J _ .. _ _ 7___ _ _ ^ ^ 5 can also be continued up to 4-5 weeks. In addition to colostrum / milk, the calves should be fed with any conventional beverage vs coarse feed.
5 Esillä olevan keksinnön etuna on omin< siltaan ja vaikutuksiltaan aiempaa parempi maitc sinnön ansiosta voidaan yksinkertaisesti emän ] nan avulla kohottaa ternimaidon immuunitekijöic toisuutta. Keksinnön mukaisesti valmistetun ko] 10 immuunitekijoiden pitoisuuden omaavan ternimaitc tasyntyneelle vasikalle antamalla edistetään se vua ja tunnetusti myös vastustuskykyä. Keksinn kainen menetelmä ei myöskään vaadi erityisiä j täisistä rutiinitoimenpiteistä poikkeavia toimei 15 tä vaan hydrolyyttisesti käsiteltyä hiivaraaka-< voidaan antaa eläimelle ruokinnan yhteydessä, i kiksi rehussa. Edelleen antamalla eläimelle hydi tisesti käsiteltyä hiivaraaka-ainetta voidaar poikimisen jälkeistä maidontuotantoa nostaa mea 20 västi. Keksinnön etuna on myös emän vastuskyvyr parantuminen poikimisen jälkeen ja täten nopea tuminen poikimisesta.An advantage of the present invention is its bridge and the effect of the present invention is due to the fact that it is possible simply to increase the immune factor of the colostrum by means of the mother. The administration of a colostrum to a neonate calf having a concentration of immune factors produced in accordance with the invention contributes to its enhancement and, as is known, resistance. Furthermore, the inventive method does not require any special action other than routine procedures, but the hydrolytically treated yeast raw material may be administered to the animal during feeding, e.g. Further, by providing the animal with a hydraulically treated yeast raw material, post-partum milk production can be increased significantly. It is also an advantage of the invention to improve the resistance of the dam after calving and thus to fast calving.
Seuraavassa keksintöä selostetaan yks iV; kohtaisesti sovellutusesimerkkien avulla viitt* « · ·’·*· 25 oheisiin kuviin, joissa • ♦ ; Kuva la esittää ruokinnan vaikutusta • * · maidon IgA pitoisuuteen, * » , Kuva Ib esittää ruokinnan vaikutusta « i eIn the following, the invention will be described in terms of one iV; specific application examples refer to the accompanying drawings in which: • ♦; Figure la shows the effect of feeding on * * · milk IgA concentration, * », Figure Ib shows the effect of feeding on« i e
IgA pitoisuuteen, jossa maitoon erittyvä IgA:n • · *···“ 3 0 on laskettu suhteessa energiakorjattuun tuotoksetIgA to the concentration where the secretion of IgA in milk • · * ··· “3 0 is calculated in relation to energy corrected yields
Kuva le esittää viikolla 3-5 tapaht * *Picture le shows events from week 3-5 * *
? * * M 4 A M Λ*Η I Λ Λ 11 . ^ n 1 «M —Ί *» «O Λ T 7\ W *» ^ Λ « Milli A W? * * M 4 A M Λ * Η I Λ Λ 11. ^ n 1 «M —Ί *« «O Λ T 7 \ W *» ^ Λ «Milli A W
6 116916, 11691
Kokeessa tutkittiin hydrolyyttisesti k lyn hiivaraaka-aineen antamisen vaikutusta mär maidon IgA pitoisuuteen, maidontuotantoon ja teettiin. Lisäksi tutkittiin mainitun maidon va 5 ta vasikoiden kasvuun.The experiment hydrolytically examined the effect of the administration of kieselguhr yeast raw material on wet milk IgA concentration, milk production, and tea. In addition, the milk content of said milk was examined for growth in calves.
Koejärjestely ja ruokintaTesting and feeding
Koetilalla tutkimukseen osallistui 23 jotka poikivat kahden kuukauden aikana kokeen a! sesta. Emät arvottiin kolmeen eri ruokintaryhmäi 10 simmäiseen ryhmään kuuluvat (8) saivat kokeen a; vanomaista väkirehua, johon oli lisätty hydro! sesti käsiteltyä hiivaraaka-ainetta (testirehu) teen toiseen ryhmään kuuluvat (7+8) saivat kaht laista tavanomaista väkirehua (kontrollirehu). 15 röllirehujen vaikutusten välillä ei havaittu joten niihin ryhmiin kuuluneiden emien tulokset tettiin tulosten käsittelyssä yhdeksi kontrolli] si (yhteensä 15).In the experimental farm, there were 23 participants who gave birth to experiment a! of. Females were judged in three different feeding groups (8) received test a; old-fashioned concentrated feed with hydro! The processed yeast raw material (test feed) of the second group of tea (7 + 8) received two conventional concentrated feed (control feed). 15 were not observed between the effects of rattlesnake, so the results of the mothers belonging to these groups were processed as one control (15 in total).
Koerehujen syöttö aloitettiin kaksi ^ 20 ennen arvioitua poikimisajankohtaa ja sitä jät) kahdeksan viikkoa poikimisen jälkeen. Testirehu ti 0,2 % hiivavalmistetta päivittäisestä annoksesta kuiva-aineena laskettuna ennen poi) :V: ja vastaavasti 0,04 - 0,06 % poikimisen jäi) ·’**· 25 tutkimusaikana.Feeding of test feeds was started two ^ 20 before and at the estimated time of calving eight weeks after calving. The test feed contained 0.2% of the daily dose of yeast preparation, calculated on a dry basis, before poi): V, and 0.04-0.06%, respectively, of calving remained) during the study period.
• · : Syntyneet vasikat arvottiin väkirehua ♦ ** · syntymäjärjestyksessä. Vasikat saivat maitoa 4 kauden ajan ja sen jälkeen muurahaishapolla hapc 1 täysmaitoa 14 vuorokauden ikäisiksi. Tämän jälke * 1 *··' 30 sikat siirrettiin hapatetulle juomarehulle kolme vän aikana asteittain. Vasikat vieroitettiin jv ·» 1 f Jmeha O τγτ ί Ιλλλ 4 Ira ΐ e i n 5 4 / «iti nm -a i ι m /\Via 1 7 tulokseen. Päivittäinen kasvu saatiin jakamalla muutos koejakson päivien lukumäärällä.• ·: Newborn calves were judged on concentrated feed ♦ ** · in order of birth. Calves received milk for 4 seasons and thereafter hapc 1 whole milk with formic acid until 14 days of age. Thereafter, * 1 * ·· '30 pigs were gradually transferred to fermented feed for three months. The calves were weaned jv · »1 f Jmeha O τγτ ί Ιλλλ 4 Ira ΐ e i n 5 4 /« iti nm -a i ι m / \ Via 1 7 result. Daily growth was obtained by dividing the change by the number of days in the trial period.
IgA pitoisuuden määrityksetIgA concentration assays
Tutkimuksessa kerättiin ternimaito- ja 5 näytteet 0, 6, ja 24 tuntia poikimisesta, sekä ja 8 viikkoa poikimisesta ja näytteiden IgA pi' det määritettiin. Tulokset on esitetty kuvissa Ib.In the study, colostrum and 5 samples at 0, 6, and 24 hours of calving, and 8 weeks of calving were collected and IgA peaks were determined. The results are shown in Figures Ib.
Maidon IgA pitoisuuden lisäksi seu: 10 emän terveyttä ja hyvinvointia. Emän poikimise keisen immuunivasteen parantumista seurattiin i maila emän maitosuonen seerumin IgA pitoisuuksi; 2, 3, 4, ja 8 viikkoa poikimisen jälkeen. Ti viikoilta 1, 4 ja 8 on esitetty kuvassa 2a.In addition to milk IgA concentration, it follows the health and well-being of 10 females. Improvement of the maternal sperm immune response was monitored by ima maternal vascular serum IgA concentration; 2, 3, 4, and 8 weeks after calving. T1 at weeks 1, 4 and 8 is shown in Figure 2a.
15 IgA vasta-ainemäärityksissä käytettii: pallista ELISA-määritystä (Bethyl Laboratories Montgommery, TX, USA). Maitonäytteet käsiteltiii 1 % BSA-puskurilla ja sentrifugoitiin (50000 c dentoista minuutin ajan. Seerumi- ja maitoni 20 laimennettiin suoraan puskuriin ilman ennakkoki lyä.15 IgA antibody assays used were: Ball ELISA (Bethyl Laboratories Montgommery, TX, USA). Milk samples were treated with 1% BSA buffer and centrifuged (50,000 c for dent minutes. Serum and milk 20 were diluted directly into the buffer without pre-treatment.
MaidontuotantoMilk production
Emän maidontuotantoa mitattiin joki ϊ.ί.ϊ lypsykerralla. Tuotantotulos 1, 2, 3, 4, 6 ja i ;***: 25 koa poikimisen jälkeen on esitetty kuvassa 2b.The mother's milk production was measured by the river ϊ.ί.ϊ at milking. Production result 1, 2, 3, 4, 6 and i; ***: 25 dogs after calving are shown in Figure 2b.
: Tulokset: Results
Maidon IgA pitoisuus ·· < Tuloksista havaitaan, että keksinnön mi i i « 9 • « *.,! ruokinta nosti ternimaidon IgA-pitoisuutta. Kuve • *·’·* 3 0 nähdään, että ternimaidon IgA pitoisuus oli ke millään poikimisajankohtana ja että se sisälsi s 4 · Ψ »m j_ _! _______ _ ___________ T _H. ____ _^ A — _ ^ i_______ i_ J - __ _ 8Milk IgA Concentration ·· <The results show that the mii i «9 •« *.,! feeding increased the IgA content of colostrum. The figure • * · '· * 3 0 shows that the IgA concentration of colostrum was Wed at any time of calving and that it contained s 4 · Ψ »m j_ _! _______ _ ___________ T _H. ____ _ ^ A - _ ^ i_______ i_ J - __ _ 8
Maidon IgA pitoisuuden vaikutus vasika vuunEffect of milk IgA concentration on calf liver
Saaduista tuloksista havaitaan, että vasta-ainepitoisuuksilla oli vaikutus vasikan k« 5 Kuvasta le nähdään, että ternimaidon IgA pit korreloi merkittävästi päivittäistä kasvua koi viiden viikon aikana (p=0,032).From the results obtained, it is observed that the antibody levels had an effect on calf k <5 Figure 5a shows that the IgA pit of colostrum significantly correlated with the daily growth of the moth over five weeks (p = 0.032).
Tutkimus osoitti myös, että emän ke> mukaisen ruokinnan avulla saatu ternimaidon pars 10 koostumus vaikutti vasikan passiiviseen immunite seerumin vasta-ainetasoja nostaen, mikä on tärke sikan terveyden kannalta.The study also showed that the pars 10 composition of colostrum produced by maternal feeding had an effect on the passive immunity of the calf raising serum antibody levels, which is important for Sika's health.
Emän immuunivaste ja maidontuotanto Kuvan 2a tuloksista havaitaan, että tes 15 män emillä immuunivaste palautui normaalille t nopeammin kuin kontrolliryhmän emillä. Emän se IgA pitoisuudet laskivat voimakkaasti ja olivat limmillaan noin viikko - kaksi poikimisen jä minkä jälkeen tasot alkoivat nousta.Maternal Immune Response and Milk Production From the results in Figure 2a, it is observed that test mothers returned to normal t faster than mothers in the control group. Maternal IgA levels declined sharply and peaked for about a week to two calving, after which levels began to rise.
20 Kuvan 2b tuloksista nähdään, että testi emät tuottivat myös enemmän maitoa kuin kontrol män emät.The results of Figure 2b show that the test females also produced more milk than the control females.
Yhteenvetona tuloksista todetaan, että olevilla menetelmillä aikaansaadaan ominaisuuks :*·*; 25 parempi maito, jonka IgA pitoisuus on kohonnut.Summarizing the results, it is noted that the present methods provide the following properties: * · *; 25 better milk with elevated IgA levels.
; ;** si menetelmien mukaisesti valmistetulla ternim * · * * la/maidolla on merkittävä vaikutus vasikan ka • i ··.·· Samalla keksinnön mukaisilla menetelmillä on my • « siä vaikutuksia sekä emän toipumiseen poikimises-30 tä maidon tuotantoon. Ternimaidon/maidon koostui paraneminen ei siis tapahdu emien kustannuksella « t « .; The colostrum produced in accordance with these methods has a significant effect on the calf's calf. The same methods of the invention also have effects on the recovery of the mother from calving to milk production. Therefore, the healing of colostrum / milk does not occur at the expense of the mothers «t«.
* · ΜΛ* a Ανηΐ I- Uv "L- aU Λ ί ΜΜΛΙή MA 4 |Um v aw m AM A 4* , 9 musten määrittelemän keksinnöllisen ajatuksen teissä, 9 9 » · « * · · • * *» ** · ΜΛ * a Ανηΐ I- Uv "L- aU Λ ί ΜΜΛΙή MA 4 | Um v aw m AM A 4 *, 9 Inventive Idea Defined by You, 9 9» · «* · · * * * *
I · II · I
• 9 9 9 • · • * * 9 9 9 999 9 9 9 * 99 9 9 9 9 9 9 9 · 999 9 9 9 9 9 9 9 99 9 9 9 9 9 9• 9 9 9 • · • * * 9 9 9 999 9 9 9 * 99 9 9 9 9 9 9 9 · 999 9 9 9 9 9 9 9 99 9 9 9 9 9 9
Claims (12)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20031538A FI116904B (en) | 2003-10-21 | 2003-10-21 | Procedure for changing the composition of the milk and the use of the milk |
| PCT/FI2004/000626 WO2005036979A1 (en) | 2003-10-21 | 2004-10-21 | Method for modifying the composition of milk and use of milk |
| EP04767132A EP1679977A1 (en) | 2003-10-21 | 2004-10-21 | Method for modifying the composition of milk and use of milk |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20031538A FI116904B (en) | 2003-10-21 | 2003-10-21 | Procedure for changing the composition of the milk and the use of the milk |
| FI20031538 | 2003-10-21 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI20031538A0 FI20031538A0 (en) | 2003-10-21 |
| FI20031538L FI20031538L (en) | 2005-04-22 |
| FI116904B true FI116904B (en) | 2006-03-31 |
Family
ID=29225978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI20031538A FI116904B (en) | 2003-10-21 | 2003-10-21 | Procedure for changing the composition of the milk and the use of the milk |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1679977A1 (en) |
| FI (1) | FI116904B (en) |
| WO (1) | WO2005036979A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1688824A1 (en) * | 1989-02-10 | 1991-11-07 | Всесоюзный Научно-Исследовательский Институт Биотехнологии | Whole milk substitute for young agricultural animals |
| US5478559A (en) * | 1991-01-15 | 1995-12-26 | National Federation Of Agricultural Cooperative Associations | Method and composition for increasing body weight and stimulating immune systems |
| CA2291487A1 (en) * | 1997-05-29 | 1998-12-03 | New Zealand Pastoral Agriculture Research Institute Limited | Processes for production of immunoglobulin a in milk |
| RU2145479C1 (en) * | 1997-11-24 | 2000-02-20 | Дальневосточный научно-исследовательский институт сельского хозяйства | Premix for cows (versions) |
| FI114895B (en) * | 2001-05-14 | 2005-01-31 | Suomen Rehu Oy | Additive for food |
| RU2229243C1 (en) * | 2002-09-02 | 2004-05-27 | Кононов Владимир Николаевич | Method for producing of feed additive |
-
2003
- 2003-10-21 FI FI20031538A patent/FI116904B/en active IP Right Grant
-
2004
- 2004-10-21 EP EP04767132A patent/EP1679977A1/en not_active Withdrawn
- 2004-10-21 WO PCT/FI2004/000626 patent/WO2005036979A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1679977A1 (en) | 2006-07-19 |
| WO2005036979A1 (en) | 2005-04-28 |
| FI20031538A0 (en) | 2003-10-21 |
| FI20031538L (en) | 2005-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0165692B1 (en) | How to change and optimize the composition of your feed | |
| EP3184120B1 (en) | Emulsified vaccine to obtain formulations of concentrated igy immunoglobulins; processes and uses for the same. | |
| Mandonnet et al. | Impact on productivity of peri-parturient rise in fecal egg counts in Creole goats in the humid tropics | |
| Muscato et al. | The effect of ruminal fluid preparations on the growth and health of newborn, milk-fed dairy calves | |
| Morgan | Some Manifestations of Animal Diseases Transmissible to Man: Brucellosis in Animals: Diagnosis and Control | |
| Burton et al. | Immunoglobulin absorption in calves as influenced by dietary protein intakes of their dams | |
| Olson et al. | Immunoglobulin levels in serum and colostral whey of protein-metabolisable energy restricted beef cows | |
| Kaskous et al. | Immunoglobulin in colostrum and health of newborn calves | |
| FI116904B (en) | Procedure for changing the composition of the milk and the use of the milk | |
| Harmon | Trace minerals and dairy cattle: importance for udder health. | |
| Furlanetti et al. | Free and total GMP (glycomacropeptide) contents of milk during bovine lactation | |
| KR100267746B1 (en) | Oral immunological preparation containing egg-yolk antibodies, for prevention and treatment of porcine diarrhea caused by enterotoxigenic escherichia coli | |
| Coyne et al. | Characterisation of Haemonchus contortus-derived cell populations propagated in vitro in a tissue culture environment and their potential to induce protective immunity in sheep | |
| Van Adrichem et al. | Effects of gastrointestinal nematodiasis on the productivity of monozygous twin cattle. II. Growth performance and milk production | |
| Lejeune et al. | Gammaglobulin and selenium status in healthy neonatal dairy calves in Switzerland | |
| Amer et al. | Influence of antepartum administration of immunopotentiators on reproductive efficacy of buffalo and viability of their newborn | |
| Amer et al. | Reproductive performance and viability of newborns in buffaloes treated antepartum with viteselen and/or ultra-corn | |
| Monni et al. | Antigenicity of Pseudodactylogyrus anguillae and P. bini (Monogenea) in the European eel (Anguilla anguilla, L.) under different oxygenation conditions | |
| CN101081299B (en) | A kind of egg yolk immunoglobulin product and application for preventing and treating Cryptosporidiosis beinii | |
| Inupala et al. | 121 Evaluation of Effects of Garlic Extract on Health Parameters and Gut Health in St. Croix Sheep | |
| JP2935193B2 (en) | Manufacturing method of therapeutic agent for rotavirus infection | |
| Golopura et al. | Influence of the medications containing phospholipids on the serum immunoglobulin g level in calves during formation of colostral immunity | |
| RU2831161C1 (en) | Method for increasing resistance in young goats of saanen breed | |
| Herlich et al. | Serological and immunological responses of calves to infection with Trichostrongylus axei | |
| NZ530709A (en) | Improved IGA production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 116904 Country of ref document: FI |